Matthew Kaplan
Stock Analyst at Ladenburg Thalmann
(2.77)
# 1,754
Out of 5,154 analysts
25
Total ratings
60.87%
Success rate
17.81%
Average return
Main Sectors:
Stocks Rated by Matthew Kaplan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $319 → $344 | $478.16 | -28.06% | 9 | Oct 31, 2024 | |
| URGN UroGen Pharma | Maintains: Buy | $48 → $54 | $20.46 | +161.49% | 1 | Jun 14, 2024 | |
| TGTX TG Therapeutics | Maintains: Buy | $39 → $40 | $29.27 | +36.66% | 3 | May 2, 2024 | |
| LQDA Liquidia | Maintains: Buy | $15 → $30 | $36.03 | -16.74% | 2 | Dec 21, 2023 | |
| ARDX Ardelyx | Maintains: Buy | $7.5 → $8.5 | $6.19 | +37.32% | 4 | Aug 3, 2023 | |
| KPRX Kiora Pharmaceuticals | Reiterates: Buy | $1,071 | $1.98 | +53,990.91% | 2 | Feb 8, 2023 | |
| XAIR Beyond Air | Maintains: Buy | $340 → $460 | $0.81 | +56,767.35% | 1 | Jun 29, 2022 | |
| LPCN Lipocine | Upgrades: Buy | $51 | $8.13 | +527.31% | 1 | Dec 10, 2020 | |
| COGT Cogent Biosciences | Initiates: Buy | $16 | $37.08 | -56.85% | 1 | Oct 14, 2020 | |
| TARA Protara Therapeutics | Initiates: Buy | $45 | $5.90 | +662.71% | 1 | Jan 22, 2020 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319 → $344
Current: $478.16
Upside: -28.06%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48 → $54
Current: $20.46
Upside: +161.49%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39 → $40
Current: $29.27
Upside: +36.66%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15 → $30
Current: $36.03
Upside: -16.74%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5 → $8.5
Current: $6.19
Upside: +37.32%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $1.98
Upside: +53,990.91%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340 → $460
Current: $0.81
Upside: +56,767.35%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $8.13
Upside: +527.31%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $37.08
Upside: -56.85%
Protara Therapeutics
Jan 22, 2020
Initiates: Buy
Price Target: $45
Current: $5.90
Upside: +662.71%